Sales growthbetter operating leverage drive earnings

Company
21 May 2024
5 Min read 
  • GSK Pharma's 4QFY24 results update and financials 
  •  Sales and EBITDA growth 
  •  Cost-saving initiatives to boost margins 
  •  Focus on specialty portfolio and vaccine business 
  •  Neutral rating maintained 
  •  Financial ratios and valuations 
  •  Summary of financials and valuations.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities